European editorial board member Aksel Siva (Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey) considers the major unmet needs in the treatment of progressive multiple sclerosis.
Speaker disclosure: Aksel Siva has received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Genzyme and , F. Hoffmann-La Roche.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!